Generation of a SARS-CoV-2 Replicon as a Model System to Dissect Virus Replication and Antiviral Inhibition
He, X.; Quan, S.; Xu, M.; Rodriguez, S.; Goh, S. L.; Wei, J.; Fridman, A.; Koeplinger, K. A.; Carroll, S. S.; Grobler, J. A.; Espeseth, A. S.; Olsen, D. B.; Hazuda, D. J.; Wang, D.
Show abstract
SARS-CoV-2 research and antiviral discovery are hampered by the lack of a cell-based virus replication system that can be readily adopted without biosafety level 3 (BSL-3) restrictions. Here, the construction of a non-infectious SARS-CoV-2 reporter replicon and its application in deciphering viral replication mechanisms and evaluating SARS-CoV-2 inhibitors are presented. The replicon genome is replication competent but does not produce progeny virions. Its replication can be inhibited by RdRp mutations or by known SARS-CoV-2 antiviral compounds. Using this system, a high-throughput antiviral assay has also been developed. Significant differences in potencies of several SARS-CoV-2 inhibitors in different cell lines were observed, which highlights the challenges of discovering antivirals capable of inhibiting viral replication in vivo and the importance of testing compounds in multiple cell culture models. The generation of a SARS-CoV-2 replicon provides a powerful platform to expand the global research effort to combat COVID-19.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A photoactivable natural product with broad antiviral activity against enveloped viruses including highly pathogenic coronaviruses 95%
- Development of a simple in vitro assay to identify and evaluate nucleotide analogs against SARS-CoV-2 RNA-dependent RNA polymerase 95%
- Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants 95%
Similar papers in this journal
- Screening and Identification of Lassa Virus Endonuclease-targeting Inhibitors from a Fragment-based Drug Development Library 96%
- SARS-CoV-2 Permissive Glioblastoma Cell Line for High Throughput Antiviral Screening 96%
- A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2 96%
Similar papers in this journal
- Development of SARS-CoV-2 replicons for the ancestral virus and variant of concern Delta for antiviral screening. 98%
- Doxycycline inhibition of a pseudotyped virus transduction does not translate to inhibition of SARS-CoV-2 infectivity 96%
- Effect of exportin 1/XPO1 nuclear export pathway inhibition on coronavirus replication. 95%
Similar papers in this journal
- Stable Cell Clones Harboring Self-Replicating SARS-CoV-2 RNAs for Drug Screen 96%
- The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral replication-transcription complex in culture cells 95%
- Inhibitors of anti-apoptotic Bcl-2 family proteins exhibit potent and broad-spectrum anti-mammarenavirus activity via cell cycle arrest at G0/G1 phase 95%
Similar papers in this journal
- Anthracyclines inhibit SARS-CoV-2 infection 97%
- Construction of Fosmid-based SARS-CoV-2 replicons for antiviral drug screening and replication analyses in biosafety level 2 facilities 96%
- The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.